Compare
TFA Therapeutics, Inc. vs Adia Med, Inc. vs China Foods Holdings Ltd. vs Nutra Pharma Corp
| Latest fiscal year | TFA Therapeutics, Inc. RAJAF | Adia Med, Inc. ADIA | China Foods Holdings Ltd. CFOO | Nutra Pharma Corp NPHC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.25M | $700.5K | $327.9K | $257.6K |
| Revenue growth (YoY) | -0.6% | n/m | +40.5% | +4.6% |
| Gross margin | 61.1% | 27.4% | 9.1% | 76.3% |
| Operating margin | -11.3% | -52.3% | -121.7% | -567.7% |
| Net margin | -12.4% | -56.5% | -121.6% | -794.8% |
| Net income | -$154.8K | -$395.5K | -$398.7K | -$2.05M |
| EPS (Diluted) | $0.00 | $0.00 | -$0.02 | $0.00 |
| Operating cash flow | -$35.8K | -$179.2K | -$389.3K | -$1.16M |
| Free cash flow | n/a | -$192.4K | n/a | -$1.19M |
| Cash & equivalents | $3.2K | $79.4K | $9.9K | $12.2K |
| Total assets | $4.66M | $594.8K | $212.9K | $584.6K |
| Total liabilities | $5.19M | $852.5K | $1.49M | $17.41M |
| Shareholders' equity | -$534.6K | -$257.7K | -$1.28M | -$16.83M |
| Return on year-end equity | n/a | n/a | n/a | n/a |
| Shares outstanding | 111.12M | n/a | 20.25M | 7.10B |
Revenue, most recent five fiscal years
| Fiscal year | TFA Therapeutics, Inc. | Adia Med, Inc. | China Foods Holdings Ltd. | Nutra Pharma Corp |
|---|---|---|---|---|
| Latest | $1.25M Ended 2025-12-31 | $700.5K Ended 2025-12-31 | $327.9K Ended 2025-12-31 | $257.6K Ended 2025-12-31 |
| 1 year earlier | $1.25M Ended 2024-12-31 | $6.4K Ended 2024-12-31 | $233.3K Ended 2024-12-31 | $246.3K Ended 2024-12-31 |
| 2 years earlier | $882.5K Ended 2023-12-31 | n/a | $158.5K Ended 2023-12-31 | $205.6K Ended 2023-12-31 |
| 3 years earlier | $53.3K Ended 2022-12-31 | n/a | $354.1K Ended 2022-12-31 | $145.8K Ended 2022-12-31 |
| 4 years earlier | $879.3K Ended 2021-12-31 | n/a | $361.1K Ended 2021-12-31 | $97.7K Ended 2021-12-31 |